Zura Bio Submits Scleroderma Drug Protocol for FDA Phase 2 Study
Zura Bio, a clinical-stage immunology company, has submitted a Phase 2 study protocol to the FDA for tibulizumab. This...
Lineage Cell Therapeutics Q3 2024 Results & Update
Lineage Cell Therapeutics announced its third quarter 2024 financial and operating results, highlighting progress in its allogeneic cell therapy...
Perspectum’s FDA Grant for Rare Disease Biomarker Evaluation
Perspectum, a medical imaging technology company, has received a substantial research grant from the U.S. Food and Drug Administration...
Cancer Patient Rights: Expanding Lifesaving Care in Illinois
A coalition of prominent cancer organizations, alongside Illinois lawmakers, is advocating for the Illinois Cancer Patients Bill of Rights....
Global Healthy Living Foundation Brings Innovative Research to ACR 2024
The Global Healthy Living Foundation (GHLF) presented groundbreaking research at the 2024 American College of Rheumatology (ACR) Convergence in...
Sparrow Pharma Presents at ACR, Expands Clofutriben Trial
Sparrow Pharmaceuticals, a clinical-stage biopharmaceutical company focused on endocrinology and rheumatology, presented interim Phase 2 trial data for clofutriben...
Koru Medical Systems Announces Q3 2024 Financial Results, Raises Guidance
KORU Medical Systems, Inc. reported strong third-quarter 2024 financial results and raised its full-year 2024 guidance for revenue, gross...
Quince Therapeutics Q3 2024 Results & Business Update
Quince Therapeutics, a late-stage biotechnology company focused on treating rare diseases, provided a pipeline update and financial results for...
Omeros Corp. Q3 2024 Financial Results
Omeros Corporation recently announced its third-quarter 2024 financial results and provided updates on its clinical development programs. The company...
Tae Life Sciences & Stella Pharma Announce BPA Strategic Agreement
TAE Life Sciences (TLS), a prominent developer of boron neutron capture therapy (BNCT) technology and related boron target drugs,...